Biotechnology - Rare diseases, Cardio-vascular

Filter

Popular Filters

Aegerion gains European approval for rare disease drug

05-08-2013

The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

US FDA accepts Ruconest filing from Santarus and Pharming

18-06-2013

US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol

22-01-2013

Netherlands-based biotech firm Dezima Pharma says it has in-licensed a cholesteryl ester transfer protein…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaImaxioLicensingMitsubishi TanabeRare diseasesSpiroleptTrolovol

FDA approves Aegerion's new orphan drug Juxtapid for rare cholesterol disorder

28-12-2012

The US Food and Drug Administration has recently approved emerging US biotech firm Aegerion Pharmaceuticals'…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularJuxtapidlomitapideNorth AmericaRare diseasesRegulation

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments

08-11-2012

US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Chelsea Thera gets disappointing news from FDA on Northera

04-07-2012

US biotech firm Chelsea Therapeutics International (Nasdaq: CHTP) shares tumbled in pre-market trading…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRare diseasesRegulation

Back to top